NorthWest Biotherapeutics Inc (NWBO)

[Margin Buu]

I do not think a peer reviewed publication has been spoiled. On the contrary it will be big when it drops if it confirms all the positive results we've heard so far.

Earlier this month, preliminary overall survival data from a major trial of DCVax-L in glioblastomas was presented at the New York Academy of Science’s ‘Frontiers in Cancer Immunotherapy 2022’ conference.

Delivered by Dr Paul Mulholland from UCLH in the UK, the results suggest that the phase III trial of 331 patients has found that DCVax-L may help extend survival for patients with newly-diagnosed or recurrent glioblastomas.

In newly-diagnosed glioblastomas, the data suggest that adding DCVax-L to treatment may offer patients nearly three months additional life on average, compared to temozolomide therapy alone – which could represent precious extra time to live.

However, while these appear to be really promising results, they are yet to be peer-reviewed and so need to be interpreted with caution at this stage.
--
From: https://www.thebraintumourcharity.org/media-centre/news/research-news/we-respond-to-promising-survival-data-from-phase-iii-trial-of-dcvax-l/

I believe this stock is heavily de-risked already, once we get a positive the peer review, it's smooth sailing. I'm not going to make a specific price prediction but I think it will be much more than your estimate, respectfully. FDA approval is one of the ultimate goals but that's not the only thing that will lift the PPS into uplist territory.